Literature DB >> 25579285

Sugammadex: what do we know and what do we still need to know? A review of the recent (2013 to 2014) literature.

T Ledowski1.   

Abstract

Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.

Entities:  

Keywords:  residual neuromuscular blockade; sugammadex

Mesh:

Substances:

Year:  2015        PMID: 25579285     DOI: 10.1177/0310057X1504300104

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  4 in total

1.  Sugammadex: watch out for new side effects.

Authors:  Yoon-Hee Kim
Journal:  Korean J Anesthesiol       Date:  2016-09-08

Review 2.  Preparing for the unexpected: special considerations and complications after sugammadex administration.

Authors:  Hajime Iwasaki; J Ross Renew; Takayuki Kunisawa; Sorin J Brull
Journal:  BMC Anesthesiol       Date:  2017-10-17       Impact factor: 2.217

3.  Important modifications by sugammadex, a modified γ-cyclodextrin, of ion currents in differentiated NSC-34 neuronal cells.

Authors:  Hung-Te Hsu; Yi-Ching Lo; Yan-Ming Huang; Yu-Ting Tseng; Sheng-Nan Wu
Journal:  BMC Neurosci       Date:  2017-01-03       Impact factor: 3.288

Review 4.  Advantages and pitfalls of clinical application of sugammadex.

Authors:  Hyung Young Lee; Ki Tae Jung
Journal:  Anesth Pain Med (Seoul)       Date:  2020-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.